New drug combo shows promise in shrinking stomach tumors before surgery
NCT ID NCT05507658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of the immunotherapy drug tislelizumab and chemotherapy (XELOX) given before surgery to 28 people with locally advanced stomach or gastroesophageal junction cancer. The goal was to see if this approach could shrink tumors more effectively and be safe. Results help explore a new treatment option for this type of cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can a smart drug home in on Hard-to-Treat cancers?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?